Comparative Pharmacology
Head-to-head clinical analysis: SEYSARA versus TETREX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SEYSARA versus TETREX.
SEYSARA vs TETREX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sarecycline is a tetracycline-class antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing the addition of amino acids to the growing peptide chain. It also has anti-inflammatory properties through inhibition of neutrophil chemotaxis and reduction of pro-inflammatory cytokines.
Tetracycline inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the A site.
100 mg orally once daily with food.
250-500 mg orally every 6 hours or 500 mg to 1 g intravenously every 6-12 hours, not to exceed 4 g/day.
None Documented
None Documented
The terminal elimination half-life after oral administration is approximately 12 hours (range 10-14 hours), supporting once-daily dosing.
Terminal elimination half-life: 6-11 hours (mean 8 hours); prolonged in renal impairment (up to 20 hours).
Renal excretion of unchanged drug accounts for approximately 66% of the administered dose; fecal elimination is about 33%.
Renal: 60% unchanged; biliary/fecal: 40% (mainly as glucuronide conjugates).
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic